



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Env-1 (191-214)
Catalog Number:	1459
Lot Number:	032577
Provided:	100 µg, 1.0 mg/ml.
Description:	Residues 191-215 from HTLV-I external glycoprotein.
Sequence:	LPHSNLDHILEPSIPWKSLLTLV.
HPLC Purity:	Purity >90% by reverse phase HPLC. Amino acid sequence analysis was used to confirm peptide sequence.
Synthesis:	Synthesized by Fmoc chemistry.
Special Characteristics:	<p>This HTLV-I peptide reacts with 92% of HTLV-I and 8.5% of HTLV-II sera tested. Env-1 is not recognized by HIV sera. This peptide has been used successfully in a "cocktail" EIA with Env-5 to distinguish HTLV-I infection from HTLV-II infection.</p> <p>Dilutions should be made in 10 mM carbonate buffer, pH 9.6 (Sigma, Catalog #C3041).</p> <p><u>Protocol: ELISA for Detection of HTLV-I and HTLV-II Positive Sera</u></p>
Recommended Storage:	Keep at -70°C.
Contributor:	Dr. Renu B. Lal.
References:	<p>Lal RB, et al. Serologic discrimination of human T cell lymphotropic virus infection by using a synthetic peptide-based enzyme immunoassay. <i>J Infect Dis</i> 163:41-46, 1991.</p> <p>Rudolph DL, Lal RB. Discrimination of human T-lymphotropic virus type-I and type-II infections by synthetic peptides representing structural epitopes from the envelope glycoproteins. <i>Clin Chem</i> 39:288-292, 1993.</p>

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HTLV-I Peptide (Env-1 191-214) from Dr. Renu Lal." Also include the references cited above in any publications.

A US Government Patent (#5738805) has been issued on this research material. Scientists at for-profit institutions or who intend commercial use of this reagent must contact Ms. Lisa Blake-DiSpigna at email address LBlake-DiSpigna@cdc.gov and specify in the email the name of the reagent, and a description of the intended use of the reagent.

Last Updated:

August 12, 2015

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.